NCT01755299

Brief Summary

The line of "5-hour Energy"® products are available over-the-counter as energy supplements. The appeal of these products involves ease of use, low caloric value, and the absence of sugar to prevent a "crash" later in the day. The definitive efficacy and potency of the products is unknown due to the lack of evidence-based clinical reports. It is suspected that the efficacy related to these products is due to the caffeine content, which was reported as 138 mg per 2-ounce bottle in an online caffeine content chart. The purpose of this randomized, double-blind, placebo controlled, four way crossover study is to evaluate the efficacy of "5-hour Energy"®, "5-Hour Energy Decaf"®, caffeine, and placebo for perceived energy and wakefulness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

December 18, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 24, 2012

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
Last Updated

July 9, 2013

Status Verified

July 1, 2013

Enrollment Period

4 months

First QC Date

December 18, 2012

Last Update Submit

July 6, 2013

Conditions

Keywords

Energy drinksWakefulnessCaffeine

Outcome Measures

Primary Outcomes (1)

  • Subjective wakefulness levels based on assessment tool rankings

    Subjects are provided with assessment tools to use for each product. The tool contains the Stanford Sleepiness Scale to assess for wakefulness levels. All appropriate options are listed, and subjects are required to circle one option at one, three, and five hours after taking the study product for the day.

    At one, three, and five hours after taking the study product

Secondary Outcomes (1)

  • Number of patients experiencing adverse effects associated with study products

    Within five hours after taking study product

Other Outcomes (1)

  • Study product consumed

    Within the five hours after taking the study product

Study Arms (4)

Active ingredient

ACTIVE COMPARATOR

Regular "5-hour Energy"

Other: Regular "5-hour Energy"

Active ingredient-2

ACTIVE COMPARATOR

"5-hour Energy Decaf"

Other: Decaf "5-hour Energy"

Active ingredient-3

ACTIVE COMPARATOR

Compounded caffeine product 135 mg/2 ounces

Other: Compounded concentrated caffeine liquid

Placebo

PLACEBO COMPARATOR

Flavored placebo

Other: Flavored bottled water

Interventions

Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)

Also known as: Original brand "5-Hour Energy" product
Active ingredient

Commercially available "5-Hour Energy Decaf" product in the amount that is packaged (1.93 fl. oz.)

Also known as: "5-hour Energy Decaf"
Active ingredient-2

Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular "5-hour Energy"

Active ingredient-3

Bottled water will be flavored and colored to serve as a placebo product for this trial.

Also known as: Water, Placebo
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Age less than 18 years
  • Subjects who are pregnant or breast-feeding
  • Diagnosis of any of the following disease states:
  • Attention Deficit Hyperactive Disorder
  • Anxiety
  • Coronary Artery Disease
  • Cardiac arrhythmias
  • Cerebral vascular accident
  • Narcolepsy
  • Seizure disorders
  • Uncontrolled hypertension
  • Active therapy with stimulant medications - any medications containing amphetamine, atomoxetine, dextroamphetamine, diethylpropion, lisdexamfetamine, methylphenidate, phentermine, or modafinil
  • Use of decongestants or other products containing phenylephrine or pseudoephedrine for more than 15 days within the past 30 days
  • Subjects who work third shift or rotate to two or more different shifts for their job, not allowing them to have a regular sleep schedule

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Flower Hospital Family Medicine Residency

Sylvania, Ohio, 43560, United States

Location

Related Links

MeSH Terms

Interventions

Water

Intervention Hierarchy (Ancestors)

HydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Pharmacy Resident

Study Record Dates

First Submitted

December 18, 2012

First Posted

December 24, 2012

Study Start

December 1, 2012

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

July 9, 2013

Record last verified: 2013-07

Locations